1. the patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study. 2. judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements. 3. psychiatric illness/social situations, or any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of participant safety or study results, or substantially increase risk of incurring aes, or compromise the ability of the patient to give written informed consent. 4. resting ecg indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, qtcf prolongation \>500 ms, electrolyte disturbances, etc.), or participants with congenital long qt syndrome 5. patients with myesthenia gravis or other neuromuscular disorders 6. patients with history of psoriasis. a. may be waived at the discretion of the pi 7. patients with history of porphyria a. may be waived at the discretion of the pi 8. concomitant use of other antiviral agents for the study's duration, but may be waived at discretion of the principal investigator 9. hypersensitivity to the study agent, or any of its excipients. 10. females who are pregnant or lactating.

1. the patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study. 2. judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements. 3. psychiatric illness/social situations, or any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of participant safety or study results, or substantially increase risk of incurring aes, or compromise the ability of the patient to give written informed consent. 4. resting ecg indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, qtcf prolongation \>500 ms, electrolyte disturbances, etc.), or participants with congenital long qt syndrome 5. patients with myesthenia gravis or other neuromuscular disorders 6. patients with history of psoriasis. a. may be waived at the discretion of the pi 7. patients with history of porphyria a. may be waived at the discretion of the pi 8. concomitant use of other antiviral agents for the study's duration, but may be waived at discretion of the principal investigator 9. hypersensitivity to the study agent, or any of its excipients. 10. females who are pregnant or lactating.

the patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study. judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements. psychiatric illness/social situations, or any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of participant safety or study results, or substantially increase risk of incurring aes, or compromise the ability of the patient to give written informed consent. resting ecg indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, qtcf prolongation >500 ms, electrolyte disturbances, etc.), or participants with congenital long qt syndrome patients with myesthenia gravis or other neuromuscular disorders patients with history of psoriasis. a. may be waived at the discretion of the pi patients with history of porphyria a. may be waived at the discretion of the pi concomitant use of other antiviral agents for the study's duration, but may be waived at discretion of the principal investigator hypersensitivity to the study agent, or any of its excipients. females who are pregnant or lactating.

the patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study. judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements. psychiatric illness/social situations, or any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of participant safety or study results, or substantially increase risk of incurring aes, or compromise the ability of the patient to give written informed consent. resting ecg indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, qtcf prolongation >500 ms, electrolyte disturbances, etc.), or participants with congenital long qt syndrome patients with myesthenia gravis or other neuromuscular disorders patients with history of psoriasis. a. may be waived at the discretion of the pi patients with history of porphyria a. may be waived at the discretion of the pi concomitant use of other antiviral agents for the study's duration, but may be waived at discretion of the principal investigator hypersensitivity to the study agent, or any of its excipients. females who are pregnant or lactating.

1. the patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study. 2. judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements. 3. psychiatric illness/social situations, or any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of participant safety or study results, or substantially increase risk of incurring aes, or compromise the ability of the patient to give written informed consent. 4. resting ecg indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, qtcf prolongation >500 ms, electrolyte disturbances, etc.), or participants with congenital long qt syndrome 5. patients with myesthenia gravis or other neuromuscular disorders 6. patients with history of psoriasis. a. may be waived at the discretion of the pi 7. patients with history of porphyria a. may be waived at the discretion of the pi 8. concomitant use of other antiviral agents for the study's duration, but may be waived at discretion of the principal investigator 9. hypersensitivity to the study agent, or any of its excipients. 10. females who are pregnant or lactating.

1. the patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study. 2. judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements. 3. psychiatric illness/social situations, or any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of participant safety or study results, or substantially increase risk of incurring aes, or compromise the ability of the patient to give written informed consent. 4. resting ecg indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, qtcf prolongation >500 ms, electrolyte disturbances, etc.), or participants with congenital long qt syndrome 5. patients with myesthenia gravis or other neuromuscular disorders 6. patients with history of psoriasis. a. may be waived at the discretion of the pi 7. patients with history of porphyria a. may be waived at the discretion of the pi 8. concomitant use of other antiviral agents for the study's duration, but may be waived at discretion of the principal investigator 9. hypersensitivity to the study agent, or any of its excipients. 10. females who are pregnant or lactating.